title: [Diagnosis of brain metastases: an update in 2012].
abstract: Diagnosis of brain metastases should aim to identify anatomoclinical entities for which a specific treatment is more accurate. Growing numbers of targeted therapies have shown to be effective against specific cancers. Several studies have reported that targeted therapies are capable of reducing brain metastases in melanoma or non small cell lung cancer (NSCLC), sometimes with a high dramatic response. These results have clearly impacted routine neuropathological practice, leading to multidisciplinary strategy management of brain metastases tissues. In accordance with the recommendations of French National Cancer Institute (INCa), the pathologist develops appropriate strategies for molecular and immunohistochemical analysis, in order to provide results as soon as possible.
authors.affiliation: CHU de Caen, Laboratoire d'anatomie pathologique, avenue de la Côte-de-Nacre, 14033 Caen cedex 9, France. lechapt-e@chu-caen.fr
authors.forename: Emmanuèle
authors.initials: E
authors.lastname: Lechapt-Zalcman
authors.forename: Marie
authors.initials: M
authors.lastname: Karanian-Philippe
authors.forename: Audrey
authors.initials: A
authors.lastname: Rousseau
mesh_terms: D001932:Brain Neoplasms / Q000235:genetics / Q000473:pathology* / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000556:secondary; D005909:Glioblastoma / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology; D008545:Melanoma / Q000235:genetics / Q000473:pathology / Q000556:secondary; D009154:Mutation; D009382:Neoplasms, Unknown Primary / Q000473:pathology
keywords: brain metastases; immunohistochemistry; pathobiology; targeted therapy; unknown primary site